Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furuta, T.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furuta, T.
Right arrow Articles by Pommier, Y.
[Cancer Research 62, 4899-4902, September 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Transcription-coupled Nucleotide Excision Repair as a Determinant of Cisplatin Sensitivity of Human Cells1

Takahisa Furuta, Takahiro Ueda, Gregory Aune, Alain Sarasin, Kenneth H. Kraemer and Yves Pommier2

Laboratory of Molecular Pharmacology [T. F., G. A., Y. P.], Basic Research Laboratory [T. U., K. H. K.], Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, and Laboratory of Genetic Instability and Cancer UPR2169 Centre National de la Recherche Scientifique, Institut de Recherches sur le Cancer, 94801 Villejuif, France [A. S.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The resistance of tumor cells to chemotherapeutic agents, such as cisplatin,is an important problem to be solved in cancer chemotherapy. One of the mechanisms associated with cisplatin resistance is nucleotide excision repair (NER). There are two pathways in NER, transcription-coupled NER (TC-NER) and global genome NER (GG-NER). Here, we report that TC-NER-deficient cells [xeroderma pigmentosum group A (XP-A), XP-D, XP-F, XP-G, Cockayne syndrome group A (CS-A), and CS-B] are hypersensitive to cisplatin irrespective of their GG-NER status, and that gene complementation with XPA and XPD increases resistance to cisplatin. By contrast, XP-C cells with selective defect in GG-NER but with normal TC-NER have normal resistance to cisplatin. XPC complementation had no effect on cisplatin antiproliferative activity. We propose that one of the pathways related to cisplatin response is TC-NER, not GG-NER.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Cisplatin is widely used for the treatment of various malignant tumors, including testicular, ovarian, head and neck, and lung (1) . The basis for the therapeutic effectiveness of cisplatin is not fully understood, but the activity of cisplatin against tumor cells is thought to be mediated through the formation of cisplatin-DNA adducts that block replication or inhibit transcription. Cisplatin forms primarily 1,2-intrastrand cross-links between adjacent purines in DNA and also introduces DNA 1,3-intrastrand cross-links, interstrand cross-links, and monoadducts (2 , 3) . Cisplatin-based chemotherapies are remarkably effective in testicular cancers, and most patients are cured with combination regimens including cisplatin, bleomycin, and etoposide (3) . Cisplatin in association with Taxol is also very effective in ovarian carcinoma, with an initial response rate of ~50% (4) . However, only 20–30% of these initial responders have a durable response, and most patients relapse (4) . Thus, a common problem for cisplatin treatments is intrinsic, as well as acquired, resistance. Resistance to cisplatin is potentially multifactorial (3) and has been attributed to decreased drug accumulation, enhanced cellular detoxification by enhanced levels of glutathione or metallothionein, and enhanced DNA repair.

NER3 is the main mechanism for removing cisplatin adducts. NER has been elucidated at the molecular level in recent years, and it is now possible to follow step by step the repair of adducts and cross-links on adjacent DNA bases (2 , 3) . The NER molecular machinery includes well-defined proteins that are mutated in XP and CS patients (5, 6, 7) . NER can be subdivided into two pathways: TC-NER and GG-NER. TC-NER repairs transcription-blocking lesions in transcribed DNA strands of active genes (7) , whereas the repair of lesions in the nontranscribed strand of active genes and nontranscribing genome ({approx}70% of the genome; Ref. 8 ) is carried out by the GG-NER pathway. Each of these subpathways consists of specific repair factors. For TC-NER, RNA polymerase II is considered the sensor for DNA damage. When transcribing RNA polymerase II encounters the lesion, two transcription-coupled repair-specific factors, CSA and CSB, are implicated for the activation of the common NER molecular pathway. For GG-NER, the XPC/hHR23B dimer engages the common NER pathway. In the common NER pathway, TFIIH and XPG bind to the DNA around the lesion. The basal transcription factor, TFIIH, contains two helicases, XPB and XPD, which open approximately a 30-base-long DNA segment around the damage. This open intermediate is stabilized by replication protein A and XPA. The DNA strand that contains the damaged base(s) is excised by the two NER endonucleases, XPG and XPF/ERCC1. XPG cleaves the damaged DNA strand 3' from the lesion, and XPF/ERCC1 cleaves the damaged strand 5' from the DNA lesion. The resulting gap is filled in by DNA polymerase {delta} or {varepsilon} in the presence of replication factors (6 , 9) .

We reported recently the selective role of TC-NER in the anticancer activity of the novel anticancer drug, Et743 a sequence-specific guanine N2 alkylator (10) . We proposed that Et743 kills cancer cells selectively in their attempt to repair transcription-blocking lesions. This finding raises the possibility that TC-NER might be a critical determinant for the antitumor activity of other anticancer drugs. The present study demonstrates the importance of TC-NER (and the apparent irrelevance of GG-NER in this context) for cellular response to cisplatin. These findings suggest the value of measuring TC-NER defects in tumors as a predictor of cellular response to cisplatin.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
The panel of cell lines used in the present study is listed in Table 1Citation . Two sets of SV40-transformed XP-C and XP-C-corrected cells, XP44RO and XP44RO+XPC, and XP4PA-SV-EB and XP4PA-SE2, were generated as described previously (11 , 12) . Other cell lines were purchased from the Coriell Institute for Medical Research (Camden, NJ). Cells were cultured in DMEM containing 10% heat-inactivated FBS. The IC50 for cisplatin was determined in each cell line by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In brief, cells were seeded into 96-well microplates at 1000 cells/100 µl in each well. Two days later after seeding, the cells were treated without or with the indicated concentrations of cisplatin. After 72 h incubation, 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma Chemical Co., Louis, MO) solution (5 mg/ml) were added to the each well. Four h later, the medium was aspirated, and 100 µl of DMSO (Sigma Chemical Co.) were added to each well. The absorbance of each well (wavelength, 550–650 nm) was measured with a microplate reader (Emax; Molecular Devices Corp., Sunnyvale, CA). The survival of cells at each concentration of drug was expressed as the percentage ratio of the absorbance of cells treated with different concentrations of cisplatin to the mean absorbance of the untreated cells. Measurements were performed in triplicate. The IC50 for cisplatin for each cell line was calculated from the dose-survival curves.


View this table:
[in this window]
[in a new window]
  		Table 1 Characteristics and IC50s for cisplatin of primary and transformed cell lines used in the study

 
Numerical data were expressed as means (±SE). The statistical significance of parameters associated with IC50s in relation to the independent effects of TC-NER proficient/deficient, GG-NER proficient/deficient, and primary/transformed status was assessed by multiple regression analysis (StatView 5.0; SAS Institute, Cary, NC). All Ps were two-sided. A value of P < 0.05 was considered statistically significant.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Cell lines derived from patients with known molecular deficiencies in each of the NER molecular subpathways were used to examine cisplatin activity (Fig. 1)Citation . We tested primary, SV40-transformed, and tumor cell lines. For the XP-A, XP-C, and XP-D cell lines, we were able to compare drug response in complemented (corrected) cells (see Table 1Citation ).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1. Schematic representation of the NER-deficient cells tested in the present study. CS cells (CS-A and CS-B) are specifically deficient for the TC-NER pathway. XP-C cells are specifically deficient for the GG-NER pathway. XP-A, XPD, XP-F, and XP-G cells are deficient for both pathways.

 
Fig. 2ACitation shows that molecular deficiencies in primary fibroblasts that are deficient in both GG-NER and TC-NER pathways (XP-A, XP-D, XP-F, and XP-G) confer marked hypersensitivity to cisplatin compared with normal primary fibroblasts.



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 2. Differential antiproliferative activity of cisplatin in TC-NER- and GG-NER-deficient cells. A, primary cells with defects in the common NER pathway (XP-D, XP-G, and XP-A) are hypersensitive to cisplatin compared with normal primary fibroblasts (AG06239 and AG13153). B, transformed cells with defects in the common NER pathway (XP-G, XP-F, XP-D, and XP-A) are hypersensitive to cisplatin compared with normal SV40-transformed fibroblasts (GM00637) and corrected cells (XP-A-Corrected and XP-D-Corrected). C, primary CS-A and CS-B cells are hypersensitive to cisplatin, whereas XP-C primary cells are resistant to cisplatin and exhibit similar response as normal cells (panel A; shaded area). D, SV40-transformed CS-B cells are hypersensitive to cisplatin, whereas SV40-transformed XP-C cells and XP-C cells from a patient tumor (XP-C*, XP44RO; XP-C-corrected*, XPC44RO+XPC) exhibit similar responses as normal cells irrespectively of correction (shaded area). Bars, SE. Shaded areas, ranges of sensitivity for primary or transformed cell lines proficient for both TC-NER and GG-NER.

 
SV40 transformation increased the sensitivity to cisplatin in normal cells. However, SV40-transformed fibroblasts from XP-A, XP-D, XP-F, or XP-G patients were hypersensitive to cisplatin compared with SV40-transformed normal cells (Fig. 2B)Citation . Complementation of the XP deficiencies by stable transfection of the deficient XP genes restored a normal phenotype for both the XP-A and XP-D cells (Fig. 2B)Citation . These results demonstrate that any one deficiency in the common NER pathway (XP-A, XP-D, XP-F, or XP-G) confers marked hypersensitivity to cisplatin.

To explore the contribution of the GG-NER and TC-NER pathways, experiments were performed with CS cells (selectively deficient for TC-NER) and XP-C cells (selectively deficient for GG-NER). Fig. 2CCitation shows that both the primary CS-A and CS-B cells were hypersensitive to cisplatin, whereas primary XP-C fibroblasts had normal sensitivity to cisplatin, and responded similarly to normal fibroblasts (AG06239 and A13153; shaded area in Fig. 2A and 2CCitation ). The SV40-transformed cells (Fig. 2D)Citation showed similar results, with CS-B cells being hypersensitive to cisplatin, whereas two sets of XP-C cells showed relative resistance to cisplatin and similar response to SV40-transformed normal fibroblasts (GM637) cells. Furthermore, correction of the XPC defect in both XP-C cell lines failed to affect cisplatin response (Fig. 2D)Citation , although the original defects in UV-induced DNA damage repair were corrected (12 , 13) .

Table 1Citation summarizes the results obtained in the cell lines examined and the relationship to the NER status of the cells. Multiple regression analysis revealed that TC-NER status was a highly significant factor affecting the responses of cells to cisplatin, and that the GG-NER status of the cells was not associated with differential activity of cisplatin (Table 2)Citation . Our analysis also demonstrated that transformed cells were significantly more sensitive to cisplatin than primary cells (Table 2)Citation .


View this table:
[in this window]
[in a new window]
  		Table 2 Multiple regression analysis of factors associated with cisplatin response

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
In the present study, we tested the cellular determinants of response and resistance to cisplatin using a panel of human cell lines with known genetic deficiencies in NER and with cell lines complemented with XPA, XPC, or XPD genes and found that the cytotoxic activity of cisplatin depends on the TC-NER status of the cells, not on their GG-NER status.

Cisplatin-DNA adducts are considered to be the main lesions that cause cellular death and therefore tumor response. The efficiency of removal of the cisplatin-DNA adducts by NER is assumed to be one of the determinants of cisplatin resistance. Recent studies have revealed that ERCC1 or ERCC1/XPF complexes (which are both essential for NER) are overexpressed in cisplatin-resistant cells (14) . Enhanced activation of other NER factors (such as XPA) has also been proposed to account for cisplatin resistance (3) . Conversely, NER mutant cells are hypersensitive to cisplatin (15) . Furthermore, testicular tumor cells, which are highly responsive to cisplatin, have been found deficient for NER because of low levels of XPA and ERCC1/XPF (16) .

Of the two NER pathways, the multiple regression analysis (Table 2)Citation revealed that only TC-NER is relevant for the antiproliferative activity of cisplatin. Thus, the transcribing genome, which represents ~30% of any given cell’s genome [if one includes both the introns and exons (8) ], appears to be of primary importance for cisplatin activity. Conversely, we found that NER deficiency in the nontranscribing genome had no effect on cisplatin activity. The three XP-C cell lines used in the present study responded to cisplatin similarly to normal fibroblast cell lines. Moreover, we found that complementation of XPC in two different XP-C cell lines had no effect on the cellular response to cisplatin. These observations imply that XPC (the GG-NER initiating factor) is dispensable for the repair of cisplatin-DNA adducts. The XPC/hHR23B complex might not detect the cisplatin-DNA adduct, as suggested by the observation that the XPC/hHR23B complex has a low affinity for cisplatin adducts (17) .

On the other hand, when one of the TC-NER-specific proteins, CSA or CSB, was deficient, we found that the cells were markedly hypersensitive to cisplatin. Interestingly, the IC50s of CS-A and CS-B cells were almost the same as those of XP-A, XP-D, XP-F, and XP-G cells that are deficient for both TC-NER and GG-NER, which is consistent with the irrelevance of GG-NER for cisplatin antiproliferative activity. Moreover, transfection of the corresponding deficient gene in two of the TCR-deficient fibroblasts (i.e., XP-A and XP-D) decreased the sensitivity to cisplatin to the levels of cells proficient for TC-NER including normal (NER proficient) and XP-C cells. These results indicate that a single deficiency in the TC-NER pathway leads to hypersensitivity to cisplatin, and that a defect of XPC in the GG-NER pathway has no effect on the cellular response to cisplatin.

Our multiple regression analysis also revealed that SV40 transformation, which blocks the function of p53 and pRb (18) , enhanced cisplatin activity independently of the TC-NER status of the cells. Recent studies revealed that p53 deficiency sensitizes cells to both cisplatin and UV radiation (15) . However, the mechanisms by which p53 deficiency sensitizes to UV and cisplatin are likely to be different. In the case of UV, p53 enhances GG-NER without affecting TC-NER (19) . In the case of cisplatin, the most plausible function of p53 in protecting cells against cisplatin is by activating the cell cycle checkpoint to extend the time for the repair of the DNA damage (19) , probably not directly related to DNA repair, because we found that GG-NER does not contribute to the antiproliferative activity of cisplatin. However, cells with inactivation of p53 are sometimes resistant to cisplatin, presumably because p53-dependent apoptotic response is inactivated (3) . Thus, we assume that the role of p53 in cisplatin response is complex and that p53 status cannot be used generally as a predictive marker of cellular response.

The response rates to cisplatin-based chemotherapy are consistently excellent in testicular tumors (16) but are unpredictable in ovarian cancers, for which more than half of the patients fail to respond either after the first course of chemotherapy or relapse (4) . The availability of tumor markers would be most useful to predict which patients will benefit from cisplatin-based chemotherapy. A recent study suggested that the high response rate of testicular tumors was related to NER deficiencies in such tumors (16) . Similarly, resistance of ovarian cancer to cisplatin is reported to be associated with increased NER activity (14) . Because we found that loss of heterozygosity of NER factors is relatively frequent in ovarian cancer (20) , differences in NER status among different tumors may underlie their sensitivity to cisplatin. Recently, the mechanism of action of Et743, a new anticancer drug in Phase II clinical trials, has been elucidated. In contrast to cisplatin, TC-NER-proficient cells are more sensitive to Et743 than TC-NER-deficient cells (10) , suggesting that cisplatin-resistant tumors should be considered a potential indication for treatment with Et743. However, in neither case was GG-NER determinant for drug responses. Together, these findings suggest that examination of the TC-NER status of cancer cells should be useful for the selection of cisplatin or Et743 in individual patients.


   ACKNOWLEDGMENTS
 
We greatly appreciated Glenda Kohlhagen’s help.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was presented at the annual meeting of American Association for Cancer Research held in San Francisco in April 2002. Back

2 To whom requests for reprints should be addressed, at Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, 37 Convent Drive, Building 37, Room 5068A, Bethesda, MD 20892-4255. Phone: (301) 496-5941; Fax: (301) 402-0752; E-mail: pommier{at}nih.gov Back

3 The abbreviations used are: NER, nucleotide excision repair; XP, xeroderma pigmentosum; CS, Cockayne syndrome; TC-NER, transcription-coupled NER; GG-NER, global genome NER; Et743, ecteinascidin 743; IC50, 50% inhibitory concentration. Back

Received 4/ 8/02. Accepted 7/15/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Cohen S. M., Lippard S. J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol., 67: 93-130, 2001.[Medline]
  2. Farrell N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Met. Ions Biol. Syst., 32: 603-639, 1996.[Medline]
  3. Kartalou M., Essigmann J. M. Mechanisms of resistance to cisplatin. Mutat. Res., 478: 23-43, 2001.[Medline]
  4. Hogberg T., Glimelius B., Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol., 40: 340-360, 2001.[Medline]
  5. Lindahl T., Karran P., Wood R. D. DNA excision repair pathways. Curr. Opin. Genet. Dev., 7: 158-169, 1997.[Medline]
  6. Hoeijmakers J. H. Genome maintenance mechanisms for preventing cancer. Nature (Lond.), 411: 366-374, 2001.[Medline]
  7. Hanawalt P. C. Controlling the efficiency of excision repair. Mutat. Res., 485: 3-13, 2001.[Medline]
  8. Venter J. C., Adams M. D., Myers E. W., Li P. W., Mural R. J., Sutton G. G., Smith H. O., Yandell M., Evans C. A., Holt R. A., et al The sequence of the human genome. Science (Wash. DC), 291: 1304-1351, 2001.[Abstract/Free Full Text]
  9. Friedberg E. C. How nucleotide excision repair protects against cancer. Nat. Rev. Cancer, 1: 22-33, 2001.[Medline]
  10. Takebayashi Y., Pourquier P., Zimonjic D. B., Nakayama K., Emmert S., Ueda T., Urasaki Y., Kanzaki A., Akiyama S. I., Popescu N., Kraemer K. H., Pommier Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med., 7: 961-966, 2001.[Medline]
  11. Lafarge-Frayssinet C., Daya-Grosjean L., Estrade S., Frezouls G., Sarasin A., Cassingena R. Cellular genes possibly involved in the transformation process of the human melanoma cell line XP44 RO (Mel). Anticancer Res., 15: 1205-1213, 1995.[Medline]
  12. Emmert S., Kobayashi N., Khan S. G., Kraemer K. H. The xeroderma pigmentosum group C gene leads to selective repair of cyclobutane pyrimidine dimers rather than 6-4 photoproducts. Proc. Natl. Acad. Sci. USA, 97: 2151-2156, 2000.[Abstract/Free Full Text]
  13. Zeng L., Quilliet X., Chevallier-Lagente O., Eveno E., Sarasin A., Mezzina M. Retrovirus-mediated gene transfer corrects DNA repair defect of xeroderma pigmentosum cells of complementation groups A, B and C. Gene Ther., 4: 1077-1084, 1997.[Medline]
  14. Ferry K. V., Hamilton T. C., Johnson S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol., 60: 1305-1313, 2000.[Medline]
  15. McKay B. C., Becerril C., Ljungman M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene, 20: 6805-6808, 2001.[Medline]
  16. Koberle B., Masters J. R., Hartley J. A., Wood R. D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol., 9: 273-276, 1999.[Medline]
  17. Batty D., Rapic-Otrin V., Levine A. S., Wood R. D. Stable binding of human XPC complex to irradiated DNA confers strong discrimination for damaged sites. J. Mol. Biol., 300: 275-290, 2000.[Medline]
  18. Ali S. H., DeCaprio J. A. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin. Cancer Biol., 11: 15-23, 2001.[Medline]
  19. Bowman K. K., Sicard D. M., Ford J. M., Hanawalt P. C. Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Mol. Carcinog., 29: 17-24, 2000.[Medline]
  20. Takebayashi Y., Nakayama K., Kanzaki A., Miyashita H., Ogura O., Mori S., Mutoh M., Miyazaki K., Fukumoto M., Pommier Y. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett., 174: 115-125, 2001.[Medline]



This article has been cited by other articles:


Home page
 JCOHome page
C. S. Walsh, S. Ogawa, H. Karahashi, D. R. Scoles, J. C. Pavelka, H. Tran, C. W. Miller, N. Kawamata, C. Ginther, J. Dering, et al.
ERCC5 Is a Novel Biomarker of Ovarian Cancer Prognosis
J. Clin. Oncol., June 20, 2008; 26(18): 2952 - 2958.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, L. Perez, J. C. Tercero, J. J. Vaquero, B. Albella, F. Gago, et al.
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Mol. Cancer Ther., May 1, 2008; 7(5): 1309 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. V. Stevens, S. Nishizuka, S. Antony, M. Reimers, S. Varma, L. Young, P. J. Munson, J. N. Weinstein, E. C. Kohn, and Y. Pommier
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers
Mol. Cancer Ther., January 1, 2008; 7(1): 10 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
Y. Pommier
DNA Repair Modulators as Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 128 - 133.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Dzagnidze, Z. Katsarava, J. Makhalova, B. Liedert, M.-S. Yoon, H. Kaube, V. Limmroth, and J. Thomale
Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy
J. Neurosci., August 29, 2007; 27(35): 9451 - 9457.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al.
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. L. Colton, X. S. Xu, Y. A. Wang, and G. Wang
The Involvement of Ataxia-telangiectasia Mutated Protein Activation in Nucleotide Excision Repair-facilitated Cell Survival with Cisplatin Treatment
J. Biol. Chem., September 15, 2006; 281(37): 27117 - 27125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yu, M. A. Mallon, W. Zhang, R. R. Freimuth, S. Marsh, M. A. Watson, P. J. Goodfellow, and H. L. McLeod
DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer
Clin. Cancer Res., September 1, 2006; 12(17): 5104 - 5111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. B. Herrero, C. Martin-Castellanos, E. Marco, F. Gago, and S. Moreno
Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin
Cancer Res., August 15, 2006; 66(16): 8155 - 8162.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Kennedy and A. D. D'Andrea
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. P. Thomas, J. Lautermann, B. Liedert, F. Seiler, and J. Thomale
High Accumulation of Platinum-DNA Adducts in Strial Marginal Cells of the Cochlea Is an Early Event in Cisplatin but Not Carboplatin Ototoxicity
Mol. Pharmacol., July 1, 2006; 70(1): 23 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
B. Liedert, D. Pluim, J. Schellens, and J. Thomale
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
Nucleic Acids Res., January 1, 2006; 34(6): e47 - e47.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Albertella, C. M. Green, A. R. Lehmann, and M. J. O'Connor
A Role for Polymerase {eta} in the Cellular Tolerance to Cisplatin-Induced Damage
Cancer Res., November 1, 2005; 65(21): 9799 - 9806.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Okuda, X. Lin, J. Trang, and S. B. Howell
Suppression of hREV1 Expression Reduces the Rate at Which Human Ovarian Carcinoma Cells Acquire Resistance to Cisplatin
Mol. Pharmacol., June 1, 2005; 67(6): 1852 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Wu, X. Lin, T. Okuda, and S. B. Howell
DNA Polymerase {zeta} Regulates Cisplatin Cytotoxicity, Mutagenicity, and The Rate of Development of Cisplatin Resistance
Cancer Res., November 1, 2004; 64(21): 8029 - 8035.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Koeppel, V. Poindessous, V. Lazar, E. Raymond, A. Sarasin, and A. K. Larsen
Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells
Clin. Cancer Res., August 15, 2004; 10(16): 5604 - 5613.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gurubhagavatula, G. Liu, S. Park, W. Zhou, L. Su, J. C. Wain, T. J. Lynch, D. S. Neuberg, and D. C. Christiani
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
J. Clin. Oncol., July 1, 2004; 22(13): 2594 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. P. Lin, M. F. Belcourt, J. G. Cory, and A. C. Sartorelli
Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(-/-) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors
J. Biol. Chem., June 25, 2004; 279(26): 27030 - 27038.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, K. D. Danenberg, V. Alberola, G. Bepler, J. J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, et al.
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 15, 2004; 10(4): 1318 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Wu, W. Fan, S. Xu, and Y. Zhou
Sensitization to the Cytotoxicity of Cisplatin by Transfection with Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense RNA in Human Lung Adenocarcinoma Cells
Clin. Cancer Res., December 1, 2003; 9(16): 5874 - 5879.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Tornaletti, S. M. Patrick, J. J. Turchi, and P. C. Hanawalt
Behavior of T7 RNA Polymerase and Mammalian RNA Polymerase II at Site-specific Cisplatin Adducts in the Template DNA
J. Biol. Chem., September 12, 2003; 278(37): 35791 - 35797.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. L. Fishel, S. M. Delaney, L. D. Friesen, R. J. Hansen, E. G. Zuhowski, R. C. Moschel, M. J. Egorin, and M. E. Dolan
Enhancement of Platinum-induced Cytotoxicity by O6-Benzylguanine
Mol. Cancer Ther., July 1, 2003; 2(7): 633 - 640.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furuta, T.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furuta, T.
Right arrow Articles by Pommier, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online